Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed Aug 14, 2024
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Award
Restricted Stock Units
2024-08-13+72,600→ 72,600 total→ Common Stock (72,600 underlying) - Award
Stock Option (Right to Buy)
2024-08-13+186,700→ 186,700 totalExercise: $9.88Exp: 2034-08-13→ Common Stock (186,700 underlying)
Holdings
- 6
Common Stock
Footnotes (3)
- [F1]The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock upon the vesting date.
- [F3]The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.